SCHEMBL4387739

SCHEMBL4387739

CCC(C)CNC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PREP P48147 1/20 0.40
FAP Q12884 1/20 0.40
CYP2C9 P11712 4/20 0.40
CYP1A2 P05177 3/20 0.40
CYP3A4 P08684 3/20 0.40
CYP2C19 P33261 3/20 0.40
POLB P06746 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
MCHR1 Q99705 1/20 0.37
CFTR P13569 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 3/20 0.37
CYP2D6 P10635 1/20 0.37
HTT P42858 1/20 0.37
IKBKE Q14164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394123 0.87 ALDH1A1 (0.41) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL4395355 0.87 ALDH1A1 (0.43) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL4383724 0.87 ALDH1A1 (0.43) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL4392406 0.87 ALDH1A1 (0.43) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL4562630 0.86 SMN1; SMN2 (0.42) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL5668017 0.85 ALDH1A1 (0.44) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL5669715 0.85 HDAC3 (0.43) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL4383435 0.84 ALDH1A1 (0.42) ALDH1A1PREPFAPCYP2C9CYP1A2
SCHEMBL2172250 0.83 MEN1 (0.45) ALDH1A1CYP2C9CYP1A2CYP3A4CYP2C19
SCHEMBL5669968 0.83 CYP1A2 (0.41) ALDH1A1PREPFAPCYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 ALDH1A1 1466/4885PREP 4562/4885FAP 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.